TABLE 2

Baseline participant demographics and characteristics (pharmacodynamics analysis set)

Participants37
Age years46.0 (18–72)
Male21 (56.8)
Body mass index kg·m−226.2±4.67
Blood eosinophils ×109 cells·L−10.242±0.1588
Race
 White35 (94.6)
 Other2 (5.4)
Screening ICS category
 Low-dose31 (83.8)
 Medium-dose6 (16.2)
Pre-bronchodilator FEV1 L2.9±0.72
Post-bronchodilator FEV1 L3.4±0.81
FEV1 pre-dose % predicted75.8 (60–96)
Reversibility L0.5±0.21
Reversibility %18.9 (12–52)
Baseline morning# PEF L·min−1422.4±107.42
Baseline evening# PEF L·min−1454.9±107.51

Data are presented as n, mean (range), n (%) or mean±sd. ICS: inhaled corticosteroids; FEV1: forced expiratory volume in 1 s; PEF: peak expiratory flow. #: morning and evening PEF are defined as the first adequate results prior to dosing for each time point.